Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is one of the best strong buy healthcare stocks to invest in. Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) released its fiscal Q4 and full-year 2025 earnings on February 25, reporting that total revenue for the year ended December 31, 2025, was $944 million compared to $705 in the previous year, considerably surpassing expectations due to continued commercial success. The company also earned substantial R&D revenue, including a $280 million upfront payment for the glo ...

In this article, we will look at the 11 Best Strong Buy Healthcare Stocks to Invest In.On February 23, Steven Wieting, CIO Group chief investment strategist, appeared on CNBC’s ‘The Exchange’ to talk about the stock market and the recent price action in stocks. CNBC reported that staples, healthcare, and utilities are all leading, outperforming since January 1 and showing that this is not a one-day trend but has rather been going on since the turn of the calendar. Wieting stated that a lot is going on in th ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

PresentationGood morning. Welcome to the JPMorgan Healthcare Conference. I'm Seiji Wakao, Japan Pharma Analyst at JPMorgan. And it's my pleasure to introduce Takino-san, CEO of Ono Pharmaceutical, and welcome him to the conference. Takino-san, please go ahead.Toichi TakinoPresident, COO & Representative Director Thank you, Wakao-san, and hello, everyone. Let me start a brief introduction. I'm Toichi Takino, President and COO of Ono Pharma from Osaka, Japan and very much honored to be here to make a presenta ...

Company Overview - Ono Pharmaceutical has a long history dating back to 1717, marking its 309th year in 2023 [3] - The company has developed numerous innovative medicines, including over 10 prostaglandin-related products and the world's first PD-1 antibody, OPDIVO, launched nearly 10 years ago [3] Growth Strategy - Ono is expanding its market focus from traditional Japan and Asia to global markets [4] - In 2024, Ono acquired U.S. biotech Deciphera, aiming to enhance its specialty products and sales channels in the U.S. and European markets [4] Future Outlook - The company is positioned as an attractive investment opportunity with high potential for future growth, driven by its development pipelines [2]

Core Insights - Deciphera Pharmaceuticals announced positive results from the Phase 2a IMPRSSION study of sapablursen for polycythemia vera (PV) at the 67th American Society of Hematology Annual Meeting [1][2] - The study demonstrated sapablursen's potential to reduce blood withdrawal rates and control hematocrit levels in phlebotomy-dependent PV patients [3][4] Company Overview - Deciphera Pharmaceuticals is a biopharmaceutical company focused on developing new medicines for cancer, neurologic, and autoimmune diseases, leveraging its proprietary switch-control kinase inhibitor platform [10] - The company is a member of Ono Pharmaceutical Co., Ltd., which aims to deliver innovative therapies and expand its global business [11] Study Details - The Phase 2a IMPRSSION study was a multicenter, randomized, open-label trial involving 49 patients, assessing the safety and efficacy of sapablursen [4] - Cohort A (32 patients) initially received 120 mg of sapablursen, later reduced to 80 mg, while Cohort B (17 patients) received 40 mg, administered subcutaneously every four weeks over a treatment period of 37 weeks [4] Efficacy Findings - The study achieved its primary endpoint, significantly decreasing the weekly phlebotomy rate from baseline to weeks 17-37: Cohort A decreased from 0.15 to 0.05 (p<0.0001) and Cohort B from 0.17 to 0.07 (p=0.0001) [7] - Median phlebotomies during the last 20 weeks of treatment were reduced to 0 in Cohort A and 1.5 in Cohort B, compared to 5 in the 26 weeks prior to treatment [7] Safety Profile - Sapablursen was generally safe and well tolerated, with one death due to acute myeloid leukemia deemed unrelated to the study drug [7][13] - Injection site reactions were mild, resolved spontaneously, and did not recur, with no adverse effects on liver or renal function observed [13] Regulatory Designations - Sapablursen received Fast Track designation in January 2024, orphan drug designation in August 2024, and Breakthrough Therapy designation in May 2025 from the U.S. FDA [3]

Core Insights - Ono Pharmaceutical Co., Ltd. has opened a new office in Zug, Switzerland, covering an area of 733 square meters to support its growth in Europe and partner markets [1] Company Expansion - The new office in Zug is part of Ono's strategy to accommodate its expanding operations in Europe [1] - The opening ceremony will feature key company executives, including CEO Gyo Sagara and President and CEO of Deciphera, Ryota Udagawa, along with regional government officials [1]

Core Insights - Fate Therapeutics has received authorization from UK and EU authorities to activate clinical trial sites for FT819, an off-the-shelf CD19-targeted CAR T-cell product candidate, aimed at improving patient accessibility with less-intensive or no conditioning [1][3] - The company reported promising preliminary clinical data for FT819, showing significant reductions in disease activity in patients with systemic lupus erythematosus (SLE) and systemic sclerosis (SSc) [5][6] - Fate Therapeutics has a strong financial position with $226 million in cash and equivalents projected to fund operations through the end of 2027 [1][12] R&D Highlights and Updates - FT819 is designed to be a cost-effective, off-the-shelf CAR T-cell therapy that can be stored for on-demand availability, overcoming limitations of traditional patient-sourced therapies [3][11] - The first patient with systemic sclerosis has been treated in a Phase 1 study, demonstrating the potential of FT819 to address significant unmet medical needs in autoimmune diseases [5][6] - FT836, another CAR T-cell candidate targeting solid tumors, has also begun patient treatment without conditioning chemotherapy, showcasing the versatility of the company's technology [7][8] Financial Results - For Q3 2025, the company reported total revenue of $1.7 million, primarily from preclinical development activities [12][17] - Total operating expenses for the same period were $36.5 million, with research and development expenses accounting for $25.8 million [12][17] - The net loss for Q3 2025 was $32.3 million, reflecting ongoing investments in R&D and operational activities [12][17] Corporate Updates - Kamal Adawi has been appointed as Chief Financial Officer, bringing over 20 years of financial leadership experience in the life sciences sector [9] - The company continues to strengthen its iPSC platform and next-generation CAR T-cell programs, focusing on expanding access to innovative therapies for patients [2][3]

Core Insights - Ono Pharmaceutical Co., Ltd. announced the presentation of data from multiple pipeline programs, including long-term and safety results from the MOTION Phase 3 study of vimseltinib for patients with TGCT where surgical removal is not an option [1] Group 1 - The MOTION Phase 3 study results will be presented at the CTOS Annual Meeting 2025, scheduled for November 12-15 in Boca Raton, Florida [1]

Core Insights - Ono Pharmaceutical Co., Ltd. announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib for patients with TGCT where surgical removal is not an option [1] Group 1 - The results will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO) scheduled for October 17-21 in Berlin, Germany [1]